2020 Environmental, Social & Governance Report
Lilly unites caring with discovery to create medicines that make life better for people around the world. For nearly 150 years, we’ve developed and delivered trusted medicines that help people get better, feel better and live better. And we remain committed to continuous progress and improving our positive impact on people, the planet and society.
A Message From Our CEO
Sustainability has always been central to Lilly, and we dedicate ourselves to ensuring our sustainability efforts help address important issues for our business, our employees and society.
2020 ESG Highlights
Debuted $35 Monthly Insulin
and helped 2M people through patient support programs for Lilly medicines
46% Women in Management Globally
22% of U.S. management positions held by minority group members
Launched the Racial Justice Initiative
to address racial injustices and to increase opportunities and equity for Black Americans
$1.8B* in Total Product Donations
and 1.2M employee volunteer service hours as part of global service day since 2008
*Value of Lilly medicines provided to patients through separate charitable organizations
Explore Our Impact
We work to continually reduce our environmental footprint with a focus on addressing climate change, waste and water security.
We improve lives and communities around the world through our medicines, our commitment to our employees and through our giving and volunteering efforts.
At Lilly, we constantly strive to be leaders in diversity and inclusion, research and development, social impact, and employee benefits. For nearly 150 years, we’ve received recognition from several distinguished organizations for our efforts.
See Our Recent Recognitions
This website contains forward-looking statements that are based on management’s current assumptions and expectations, including statements regarding our sustainability targets, goals, commitments and programs and other business plans, initiatives and objectives. The words “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate” and similar expressions are intended to identify forward-looking statements. All such statements are intended to enjoy the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially due to various factors. The company’s sustainability targets, goals, and commitments outlined in this website or elsewhere, as well as its operations, results, business, goals, and strategy may be affected by factors including, but not limited to, the impact of the evolving COVID-19 pandemic and the global response thereto; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; competitive developments affecting current products and the company’s pipeline; regulatory actions regarding currently marketed products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured; the impact of business development transactions and related integration costs; the impact of global macroeconomic conditions and trade disruptions or disputes; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company expressly disclaims any obligation to update forward-looking statements except as required by applicable law.